Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.

MLA

Sood, Siddhartha, et al. “Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-Week Multicenter Retrospective Review.” Journal of the American Academy of Dermatology, Aug. 2024. EBSCOhost, https://doi.org/10.1016/j.jaad.2024.07.1515.

APA

Sood, S., Rimke, A., Rankin, B. D., Abduelmula, A., Georgakopoulos, J. R., Maliyar, K., Bagit, A., Leung, F., Devani, A. R., Vender, R., Yeung, J., & Prajapati, V. H. (2024). Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.07.1515

Chicago

Sood, Siddhartha, Alexander Rimke, Brian D Rankin, Abrahim Abduelmula, Jorge R Georgakopoulos, Khalad Maliyar, Ahmed Bagit, et al. 2024. “Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-Week Multicenter Retrospective Review.” Journal of the American Academy of Dermatology, August. doi:10.1016/j.jaad.2024.07.1515.